MedTrace Logo

Significance of Misoprostol-induced Cervical Ripening Prior to Hysteroscopy

NCT06726278 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 539

Last updated 2024-12-10

No results posted yet for this study

Summary

The goal of this prospective study is to evaluate the efficacy and safety of misoprostol for cervical ripening prior to hysteroscopy

Conditions

  • Hysteroscopy
  • Cervical Ripening

Interventions

DRUG

Misoprostol 400mcg Tab

Misoprostol 400 µg is a synthetic prostaglandin E1 analog used in this clinical trial to evaluate its effects in inducing uterine contractions or labor. This dosage form is typically administered orally, and its primary mechanism involves the softening and dilation of the cervix, making it a common choice in obstetric practices for labor induction. The study will evaluate its efficacy and safety profile when compared to the placebo group. Misoprostol is administered in a single dose of 400 µg, and participants will be monitored for any adverse reactions or labor-related outcomes.

DRUG

Placebo

participants will receive a placebo treatment, consisting of an inert substance that has no active pharmacological effect. The placebo is administered in the same manner (vaginally) and at the same time point as Misoprostol, but without any therapeutic action. This group is used to control for potential psychological effects of the intervention, ensuring that any observed

Sponsors & Collaborators

  • Khyber Teaching Hospital

    collaborator OTHER

  • Hayat Abad Medical Complex, Peshawar.

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2024-07-30
Completion
2024-07-30

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06726278 on ClinicalTrials.gov